| A ALL00P2 |
Leukemia, Acute |
|
COG |
CL |
10/4/2005 |
1 |
0 |
0 |
0 |
|
| A3973 |
Brain |
|
COG |
CL |
3/31/2006 |
1 |
0 |
0 |
0 |
|
| A5971 |
Lymphomas |
A5971 |
COG |
CL |
7/30/2007 |
1 |
0 |
0 |
0 |
|
| AALL0031 |
Leukemia, Acute |
|
COG |
CL |
10/20/2006 |
2 |
0 |
0 |
0 |
|
| AALL01P2 |
Leukemia, Acute |
|
COG |
CL |
12/30/2005 |
2 |
0 |
0 |
0 |
|
| AALL0232 |
Leukemia, Acute |
|
COG |
AC |
|
2 |
0 |
0 |
0 |
|
| AALL02P2 |
Leukemia, Acute |
|
COG |
AC |
|
2 |
0 |
0 |
0 |
|
| AALL0331 |
Leukemia, Acute |
|
COG |
AC |
|
2 |
0.5 |
0 |
0 |
Cancer control credit for QOL. Note: Treatment credit increased from 1.0 to 2.0 (should have received 2.0 initially since it is an ALL in children). |
| AALL03N1 |
Descriptive |
|
|
Active |
|
|
0.5 |
0 |
|
Credit is for CCOPs and non-CCOP members and affiliates. The Research Base will only receive credit for non-CCOP members/affiliate accruals (for per case payment) since an R01 grant covers the funds for the study design, conduct and analysis. |
| AALL0433 |
Leukemia, Acute |
|
COG |
AC |
|
2 |
0 |
0 |
0 |
|
| AALL0434 |
Leukemia, Acute |
|
COG |
AC |
|
2 |
0 |
0 |
0 |
|
| AALL0631 |
Leukemia, Acute |
|
COG |
AC |
|
2 |
0 |
0 |
0 |
|
| AAML00P2 |
Leukemia, Acute |
|
COG |
CL |
4/20/2006 |
1 |
0 |
0 |
0 |
|
| AAML0122 |
Leukemia, Chronic |
|
COG |
CL |
10/23/2006 |
1 |
0 |
0 |
0 |
|
| AAML0123 |
Leukemia, Chronic |
|
COG |
CL |
10/20/2006 |
1 |
0 |
0 |
0 |
|
| AAML03P1 |
Leukemia, Acute |
|
COG |
CL |
11/1/2005 |
1 |
0 |
0 |
0 |
|
| AAML0431 |
Leukemia, Acute |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AAML0523 |
Leukemia, Chronic |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AAML0531 |
Leukemia, Acute |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AAML0532 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ACCL0131 |
Descriptive |
ACCL0131 |
|
Closed |
6/29/2007 |
0 |
0.7 |
0 |
|
|
| ACCL01P3 |
Intervention Study |
|
|
Closed |
2/28/2005 |
|
0.5 |
0 |
|
|
| ACCL0331 |
Intervention Study |
|
|
Closed |
11/7/2006 |
0 |
1 |
|
|
|
| ACCL0422 |
Other |
|
HLMCC |
AC |
|
0 |
1 |
0 |
0 |
COG is participating in this HLMCC 02 01 protocol |
| ACCL0423 |
Other |
|
HLMCC |
AC |
|
0 |
1 |
0 |
0 |
COG is participating in HLMCC 0205 protocol |
| ACCL04C2 |
Intervention Study |
|
|
Active |
|
0 |
1 |
0 |
|
|
| ACCL05C1 |
|
|
|
Active |
|
0 |
1 |
0 |
|
|
| ACNS0026 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ACNS0121 |
Brain |
|
COG |
CL |
11/21/2007 |
1 |
0 |
0 |
0 |
|
| ACNS0122 |
|
|
COG |
AC |
|
1 |
|
0 |
0 |
|
| ACNS0126 |
Brain |
|
COG |
CL |
9/6/2005 |
1 |
0 |
0 |
0 |
|
| ACNS0221 |
Brain |
|
COG |
AC |
|
1 |
0.5 |
0 |
0 |
Cancer Control credit for QOL |
| ACNS0222 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ACNS0223 |
Brain |
|
COG |
CL |
8/3/2007 |
1 |
0 |
0 |
0 |
|
| ACNS0224 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ACNS0226 |
Brain |
|
COG |
CL |
9/5/2006 |
1 |
0 |
0 |
0 |
|
| ACNS0232 |
Brain |
|
COG |
AC |
|
1 |
0.5 |
0 |
0 |
Cancer Control credit for QOL |
| ACNS0331 |
Brain |
|
COG |
AC |
|
1 |
0.5 |
0 |
0 |
0.5 Cancer Control credit for QOL |
| ACNS0332 |
Brain |
|
COG |
AC |
|
1 |
0.5 |
0 |
0 |
0.5 Cancer control credit for QOL component |
| ACNS0334 |
Brain |
|
COG |
AC |
|
1 |
0.5 |
0 |
0 |
0.5 Cancer Control credit is for QOL |
| ACNS0423 |
Brain |
|
COG |
CL |
10/26/2007 |
1 |
0 |
0 |
0 |
|
| ADVL0015 |
Other |
|
COG |
CL |
2/17/2003 |
1 |
0 |
0 |
0 |
|
| ADVL0016 |
Other |
|
COG |
CL |
10/22/2004 |
1 |
0 |
0 |
0 |
|
| ADVL0022 |
Leukemia, Acute |
|
COG |
CL |
4/21/2003 |
2 |
|
0 |
0 |
|
| ADVL0023 |
Leukemia, Acute |
|
COG |
CL |
3/20/2006 |
1 |
0 |
0 |
0 |
|
| ADVL0024 |
Brain |
|
COG |
CL |
6/1/2006 |
1 |
|
0 |
0 |
|
| ADVL0122 |
Sarcoma |
|
COG |
CL |
10/15/2004 |
1 |
0 |
0 |
0 |
|
| ADVL0221 |
Solid |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ADVL0421 |
Other |
|
COG |
CL |
7/31/2007 |
1 |
0 |
0 |
0 |
|
| ADVL04P2 |
Leukemia, Acute |
|
COG |
AC |
|
2 |
0 |
0 |
0 |
|
| ADVL0524 |
Other |
|
COG |
CL |
10/26/2007 |
1 |
0 |
0 |
0 |
|
| ADVL0525 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AEWS0031 |
Sarcoma |
AEWS0031 |
COG |
CL |
8/6/2005 |
1 |
0 |
0 |
0 |
|
| AEWS02B1 |
Sarcoma |
|
COG |
AC |
|
0.1 |
0 |
0 |
0 |
|
| AEWS02P1 |
Sarcoma |
|
COG |
AC |
|
1 |
|
0 |
0 |
|
| AEWS0331 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AEWS0421 |
Sarcoma |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AEWS0521 |
Sarcoma |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AEWS0531 |
Sarcoma |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AEWS0621 |
Sarcoma |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AGCT0132 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AGCT01P1 |
Other |
|
COG |
CL |
8/3/2007 |
1 |
0 |
0 |
0 |
|
| AGCT0521 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AHOD0031 |
Lymphomas, Hodgkin's Disease |
|
COG |
AC |
|
1 |
|
0 |
0 |
|
| AHOD00P1 |
Lymphomas, Hodgkin's Disease |
|
COG |
CL |
3/20/2006 |
1 |
0 |
0 |
0 |
|
| AHOD0121 |
Lymphomas, Hodgkin's Disease |
|
COG |
CL |
6/8/2007 |
1 |
0 |
0 |
0 |
|
| AHOD0321 |
Lymphomas, Hodgkin's Disease |
|
COG |
CL |
6/8/2007 |
1 |
0 |
0 |
0 |
|
| AHOD03P1 |
Lymphomas, Hodgkin's Disease |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AHOD0431 |
Lymphomas, Hodgkin's Disease |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AHOD0521 |
Lymphomas, Hodgkin's Disease |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ALTE02C2 |
Descriptive |
|
|
Active |
|
|
0.5 |
|
|
|
| ALTE03N1 |
Other |
|
COG |
AC |
|
0 |
0.1 |
0 |
0 |
|
| ALTE04N1 |
|
|
|
Active |
|
0 |
0.5 |
0 |
|
Credit is for CCOPs and non-CCOP institutions only. The research base receives NO credit because of R01 funding for the data analysis, etc. |
| ANBL0032 |
Brain |
ANBL0032 |
COG |
AC |
|
1 |
|
0 |
0 |
|
| ANBL00P2 |
Brain |
|
COG |
AC |
|
0 |
0 |
0 |
0 |
No credit assigned for observational trial |
| ANBL00P3 |
Brain |
|
COG |
AC |
|
1 |
|
0 |
0 |
|
| ANBL0321 |
Brain |
|
COG |
CL |
12/17/2004 |
1 |
0 |
0 |
0 |
|
| ANBL0322 |
Brain |
|
COG |
CL |
9/25/2007 |
1 |
0 |
0 |
0 |
|
| ANBL0421 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ANBL0531 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ANBL0532 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ANBL0621 |
Brain |
|
COG |
AC |
|
1 |
0.5 |
0 |
0 |
0.5 Cancer Control credit for QOL |
| ANHL0121 |
Lymphomas Non-Hodgkin's |
|
COG |
CL |
10/23/2006 |
1 |
0 |
0 |
0 |
|
| ANHL0131 |
Lymphomas |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ANHL01P1 |
Lymphomas |
|
COG |
AC |
|
1 |
|
0 |
0 |
|
| ANHL0221 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ANUR0532 |
Intervention Study |
|
|
DCP Approved |
|
0 |
1 |
0 |
|
|
| ANUR0631 |
Intervention Study |
|
|
Active |
|
0 |
1 |
0 |
|
|
| AOST0121 |
Sarcoma |
AOST0121 |
COG |
CL |
11/9/2005 |
1 |
0 |
0 |
0 |
|
| AOST0221 |
Sarcoma |
|
COG |
AC |
|
1 |
|
0 |
0 |
|
| AOST0331 |
Sarcoma |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARAR0331 |
Head and Neck |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARAR0332 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AREN0321 |
Genitourinary |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AREN0532 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| AREN0533 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARET0231 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARET0321 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARET0331 |
Other |
|
COG |
AC |
|
1 |
|
0 |
0 |
|
| ARET0332 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARST0121 |
Sarcoma |
|
COG |
CL |
10/27/2006 |
1 |
0 |
0 |
0 |
|
| ARST0321 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARST0331 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARST0332 |
Sarcoma |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARST03P1 |
Sarcoma |
|
COG |
CL |
1/19/2007 |
1 |
0 |
0 |
0 |
|
| ARST0431 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ARST0531 |
Brain |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ASCT0431 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ASCT0521 |
Other |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| ASCT0631 |
Leukemia, Acute |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|
| BMT-CTN 0501 |
Leukemia, Chronic |
|
COG |
AC |
|
1 |
0 |
0 |
0 |
|